Method for the diagnosis, prognosis and treatment of lung cancer metastasis
The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
1. A method for treating and/or preventing bone metastasis in a subject suffering lung cancer with elevated c-MAF levels in a metastatic tumor sample with respect to a control sample, comprising administering a therapeutically effective amount of an agent capable of treating, reducing and/or preventing bone degradation to the subject suffering lung cancer, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab.
2. The method according to claim 1 , wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab.
3. The method according to claim 1 , wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid.
4. The method according to claim 1 , wherein the lung cancer is small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC).
5. The method according to claim 1 , wherein the bone metastasis is osteolytic metastasis.
6. The method according to claim 1 , wherein the lung cancer is lung adenocarcinoma.
7. A method for treating and/or preventing bone metastasis in a subject suffering lung cancer, said method comprising administering to said subject an agent capable of treating, reducing and/or preventing bone degradation, wherein said agent is administered in accordance with a treatment regimen determined from quantifying the expression level, gene copy number or amplification of c-MAF in said subject, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab.
8. A method for treating a subject suffering lung cancer which comprises
i) quantifying the c-MAF gene expression level, gene copy number or amplification in a sample of said subject and
ii) comparing the value obtained in i) with a reference value,
wherein if the value is increased with respect to said reference value, then said subject is administered a therapeutically effective amount of an agent capable of treating, reducing and/or preventing bone degradation, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab.
9. The method according to claim 7 , wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab.
10. The method according to claim 7 , wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid.
11. The method according to claim 7 , wherein the lung cancer is SCLC or NSCLC or lung adenocarcinoma.
12. The method according to claim 7 , wherein the bone metastasis is osteolytic metastasis.
13. The method according to claim 8 , wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab.
14. The method according to claim 8 , wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid.
15. The method according to claim 8 , wherein the lung cancer is SCLC or NSCLC or lung adenocarcinoma.
16. The method according to claim 1 , wherein the method is a method for treating bone metastasis.
17. The method according to claim 7 , wherein the method is a method for treating bone metastasis.
18. The method of any one of claims 1 , 7 or 8 , wherein the agent capable of treating, reducing and/or preventing bone degradation is an agent capable of treating and/or reducing bone degradation.
19. The method according to claim 1 , wherein the lung cancer is SCLC.
20. The method according to claim 1 , wherein the lung cancer is NSCLC.
21. The method according to claim 1 , wherein the subject is a human.
22. The method according to claim 7 , wherein the lung cancer is SCLC.
23. The method according to claim 7 , wherein the lung cancer is NSCLC.
24. The method according to claim 7 , wherein the lung cancer is lung adenocarcinoma.
25. The method according to claim 7 , wherein the subject is a human.
26. The method according to claim 8 , wherein the lung cancer is SCLC.
27. The method according to claim 8 , wherein the lung cancer is NSCLC.
28. The method according to claim 8 , wherein the lung cancer is lung adenocarcinoma.
29. The method according to claim 8 , wherein the subject is a human.